ACADIA Pharmaceuticals Files Q3 2024 10-Q
Ticker: ACAD · Form: 10-Q · Filed: 2024-11-07T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financials
TL;DR
**ACADIA PHARMACEUTICALS FILES Q3 2024 10-Q - CHECK FINANCIALS NOW**
AI Summary
ACADIA Pharmaceuticals Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and provided updates on its business operations. Key financial figures and operational details are disclosed in this filing, which is crucial for investors to assess the company's performance and outlook.
Why It Matters
This filing provides investors with the latest financial performance and operational details for ACADIA Pharmaceuticals, enabling informed investment decisions.
Risk Assessment
Risk Level: medium — The company operates in the highly regulated and competitive pharmaceutical industry, facing risks related to drug development, clinical trials, and market approval.
Key Numbers
- 2024-09-30 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial data is reported.)
- 2024-11-07 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
- 2834 — SIC Code (Standard Industrial Classification code for Pharmaceutical Preparations.)
Key Players & Entities
- ACADIA PHARMACEUTICALS INC (company) — Filer of the 10-Q
- 2024-09-30 (date) — End of the reporting period
- 2024-11-07 (date) — Filing date
- Nuplazid (product) — Mentioned in relation to a specific period
- Stoke Therapeutics Inc (company) — Mentioned in relation to R&D expense
FAQ
What were ACADIA Pharmaceuticals' key financial highlights for the quarter ending September 30, 2024?
The filing is a 10-Q which provides financial statements and disclosures for the period ending September 30, 2024, but specific dollar amounts for revenue, net income, or EPS are not detailed in the provided header information.
What is the primary business of ACADIA Pharmaceuticals Inc.?
ACADIA Pharmaceuticals Inc. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted to the SEC on November 7, 2024.
What is the fiscal year end for ACADIA Pharmaceuticals Inc.?
The fiscal year end for ACADIA Pharmaceuticals Inc. is December 31.
Are there any specific product names mentioned in the filing header?
Yes, 'Nuplazid' is mentioned in the context of a specific reporting period (July 1, 2023 to September 30, 2023).
Filing Stats: 4,290 words · 17 min read · ~14 pages · Grade level 16.2 · Accepted 2024-11-06 17:41:01
Key Financial Figures
- $0.0001 — ch Registered Common Stock, par value $0.0001 per share ACAD The Nasdaq Stock Mar
Filing Documents
- acad-20240930.htm (10-Q) — 1830KB
- acad-ex10_6.htm (EX-10.6) — 114KB
- acad-ex31_1.htm (EX-31.1) — 11KB
- acad-ex31_2.htm (EX-31.2) — 11KB
- acad-ex32_1.htm (EX-32.1) — 8KB
- acad-ex32_2.htm (EX-32.2) — 8KB
- img94628292_0.jpg (GRAPHIC) — 161KB
- 0000950170-24-122513.txt ( ) — 7809KB
- acad-20240930.xsd (EX-101.SCH) — 919KB
- acad-20240930_htm.xml (XML) — 1390KB
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION Item 1.
Financial Statements
Financial Statements 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations 2 Condensed Consolidated Statements of Comprehensive Income (Loss) 3 Condensed Consolidated Statements of Cash Flows 4 Condensed Consolidated Statements of Stockholders' Equity 5 Notes to Condensed Consolidated Financial Statements 6 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 27 Item 4.
Controls and Procedures
Controls and Procedures 28
OTHER INFORMATION
PART II. OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 29 Item 1A.
Risk Factors
Risk Factors 29 Item 5. Other Information 63 Item 6. Exhibits 65
SIGNATURES
SIGNATURES 67 i
FINANCI AL INFORMATION
PART I. FINANCI AL INFORMATION
F INANCIAL STATEMENTS
ITEM 1. F INANCIAL STATEMENTS ACADIA PHARMACEUTICALS INC. CONDENSED CONSOLIDA TED BALANCE SHEETS (in thousands, except share and per share amounts) September 30, 2024 December 31, 2023 (unaudited) Assets Cash and cash equivalents $ 155,149 $ 188,657 Investment securities, available-for-sale 410,181 250,208 Accounts receivable, net 98,209 98,267 Interest and other receivables 12,154 4,083 Inventory 61,041 35,819 Prepaid expenses 51,550 39,091 Total current assets 788,284 616,125 Property and equipment, net 3,988 4,612 Operating lease right-of-use assets 44,253 51,855 Intangible assets, net 105,515 65,490 Restricted cash 8,770 5,770 Long-term inventory 25,699 4,628 Other assets 359 476 Total assets $ 976,868 $ 748,956 Liabilities and stockholders' equity Accounts payable $ 19,081 $ 17,543 Accrued liabilities 324,864 236,711 Total current liabilities 343,945 254,254 Operating lease liabilities 40,421 47,800 Other long-term liabilities 15,322 15,147 Total liabilities 399,688 317,201 Commitments and contingencies (Note 9) Stockholders' equity: Preferred stock, $ 0.0001 par value; 5,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding at September 30, 2024 and December 31, 2023 — — Common stock, $ 0.0001 par value; 225,000,000 shares authorized at September 30, 2024 and December 31, 2023; 166,351,715 shares and 164,650,219 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 16 16 Additional paid-in capital 2,924,434 2,862,552 Accumulated deficit ( 2,348,128 ) ( 2,430,837 ) Accumulated other comprehensive income 858 24 Total stockholders' equity 577,180 431,755 Total liabilities and stockholders' equity $ 976,868 $ 748,956 The accompanying notes are an integral part of these unaudited c